[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-reservoir\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-reservoir":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100641318","intestinal-tissue-resident-memory-t-cells-and-hiv-1-persistence-during-antiretroviral-therapy-100641318",false,"NCT07656077","Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy","Intestinal Tissue-Resident Memory T Cells in HIV-1 Infection: Mechanisms Involved in Their Depletion and Role in Viral Persistence During Antiretroviral Therapy","ANRSGALT-2","I - Inclusion criteria\n\n1 - Group 1: People Living With HIV-1\n\n* Age ≥ 18 years\n* Documented HIV-1 infection\n* Continuous suppressive antiretroviral therapy initiated during chronic infection for at least 12 months\n* Plasma HIV-1 RNA ≤ 50 copies\u002FmL for at least 6 months under ART (one isolated blip ≤ 200 copies\u002FmL allowed)\n* Blood CD4+ T-cell count ≥ 350 cells\u002Fmm³\n* Clinically indicated colonoscopy independent of the research protocol\n* Affiliation with a social security system\n* Written informed consent obtained before any study-specific procedure\n\n  2- Group 2: HIV-Seronegative Controls\n* Age ≥ 18 years\n* HIV-seronegative status\n* Clinically indicated colonoscopy independent of the research protocol\n* Affiliation with a social security system\n* Written informed consent obtained before any study-specific procedure\n\nII - Exclusion Criteria\n\n1. Group 1: People Living With HIV-1\n\n   * HIV-2 infection\n   * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or celiac disease\n   * Platelet count \\\u003C 50 G\u002FL or uncorrectable coagulation disorders contraindicating biopsies\n   * Decompensated cirrhosis\n   * History of lymphoma\n   * Participation in an HIV vaccine or immunotherapy study\n   * Pregnant or breastfeeding women\n   * Participation in another clinical study with an ongoing exclusion period\n   * Vulnerable individuals, including minors, individuals under guardianship, or persons deprived of liberty\n2. Group 2: HIV-Seronegative Controls\n\n   * HIV-1 or HIV-2 infection\n   * Refusal to undergo HIV serology testing\n   * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or celiac disease\n   * Platelet count \\\u003C 50 G\u002FL or uncorrectable coagulation disorders contraindicating biopsies\n   * Decompensated cirrhosis\n   * History of lymphoma\n   * Pregnant or breastfeeding women\n   * Participation in another clinical study with an ongoing exclusion period\n   * Vulnerable individuals, including minors, individuals under guardianship, or persons deprived of liberty",true,"ALL","18 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study aims to better characterize intestinal tissue-resident memory T cells (TRM) in people living with HIV-1 receiving suppressive antiretroviral therapy (ART). TRM cells are key components of tissue immunity and may contribute to HIV-1 persistence within the intestinal mucosa, a major viral reservoir. The phenotypic, transcriptomic, and functional characteristics of intestinal CD4+ and CD8+ TRM cells, their susceptibility to HIV-1 infection, and their potential role as viral reservoirs will be investigated. Blood samples and additional colonic biopsies obtained during routine clinically indicated colonoscopy will be collected from HIV-1-infected participants and HIV-seronegative controls.",[28,29,30],"HIV-1 Infection","HIV Reservoir","Antiretroviral Therapy",[32,33,34,35,36,37,38,39],"HIV-1","Tissue-Resident Memory T Cells","Viral Reservoir","ART","Intestinal Mucosa","Mucosal Immunity","CD4 T Cells","HIV Persistence","NOT_YET_RECRUITING","2026-06-14",{"date":43,"type":44},"2026-06-18","ACTUAL",{"date":46,"type":22},"2026-08-01",{"date":48,"type":22},"2030-07-31",{"name":50,"class":51},"ANRS, Emerging Infectious Diseases","OTHER_GOV"]